Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non-Current Debt: 2013-2024

Historic Non-Current Debt for Ironwood Pharmaceuticals (IRWD) over the last 8 years, with Dec 2024 value amounting to $385.0 million.

  • Ironwood Pharmaceuticals' Non-Current Debt fell 3.75% to $385.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $385.0 million, marking a year-over-year decrease of 3.75%. This contributed to the annual value of $385.0 million for FY2024, which is 28.33% up from last year.
  • As of FY2024, Ironwood Pharmaceuticals' Non-Current Debt stood at $385.0 million, which was up 28.33% from $300.0 million recorded in FY2023.
  • Ironwood Pharmaceuticals' 5-year Non-Current Debt high stood at $385.0 million for FY2024, and its period low was $300.0 million during FY2023.
  • Its 2-year average for Non-Current Debt is $342.5 million, with a median of $342.5 million in 2023.
  • Data for Ironwood Pharmaceuticals' Non-Current Debt shows a peak YoY rose of 28.33% (in 2024) over the last 5 years.
  • Ironwood Pharmaceuticals' Non-Current Debt (Yearly) stood at $300.0 million in 2023, then rose by 28.33% to $385.0 million in 2024.